Back to Results
First PageMeta Content
Oncology / Phosphoinositide 3-kinase / AKT / PTEN / HER2/neu / Breast cancer / Akt/PKB signaling pathway / Phosphoinositide-dependent kinase-1 / Medicine / Biology / Protein kinases


Abstract 928 AACR 2012 The novel clinical candidate AT13148 is an oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity and a mechanism of action distinct from AKT inhibitors
Add to Reading List

Open Document

File Size: 1,21 MB

Share Result on Facebook

City

London / Cambridge / Sutton / /

Company

2Astex Pharmaceuticals / Cancer Research Technology / AstraZeneca / Astex Therapeutics Ltd / /

Country

United Kingdom / /

Event

FDA Phase / /

Facility

The Institute of Cancer Research / The Institute of Cancer / Institute of Cancer Research / /

MedicalCondition

U87MG glioblastoma cells Both / cancers / tumor / BT474 tumor / PIK3CA-mutant BT474 breast cancer / cancer / Nature Reviews Cancer / MES-SA human uterine sarcoma / PTENdeficient PC3 human prostate cancer / established human tumor / MES-SA uterine tumor / human cancers / /

MedicalTreatment

anticancer therapies / /

Organization

NHS / Michelle D. Garrett1 1The Institute of Cancer Research / 3Cancer Research UK Drug Development Office / /

Person

Aurora B Kinase / LY D AKT VASP / /

Product

AT13148 / /

PublishedMedium

Nature Reviews Cancer / Cancer Research / /

Technology

X-ray / DNA Chip / gene expression / apoptosis / /

SocialTag